概況
公司主要生產人類蛋白組抗體及相關產品。目前已有多克隆抗體10000多種，單克隆抗體300餘種，融合蛋白13000多種，即已經完成了人類基因組三分之一以上的基因的表達，成為全球最大的重組蛋白生產公司。此外，公司還有人類全長cDNA 22000條，並擁有自己的實驗動物基地。公司產品以出口為主，目前已在美、日、歐洲各國的生物醫學領域擁有穩定的顧客群。
武漢三鷹生物技術有限公司地位
武漢三鷹生物技術有限公司成立之初，即瞄準了蛋白質組研究這一巨大的市場，並提出了抗體組的概念。抗體是識別研究蛋白質必不可少的工具，三鷹生物的目標是實施人類抗體組計畫，即研究和製備人類蛋白組中所有蛋白質的抗體，探索大規模製備抗體的新技術，並完善抗原－抗體相互作用的高通量化、自動化及智慧型化的檢測技術。目前已經是國內最大的抗體公司，也是全球抗體公司中最大規模的公司之一。公司產品90%以上銷往歐美地區，在同行業中占首位。
技術
武漢三鷹生物技術有限公司在美國設有專家顧問團，擁有強有力的技術支持後盾和培訓力量；公司的骨幹力量是一群朝氣蓬勃的年輕人，武漢三鷹生物技術有限公司已經成功地將實驗室的分子生物學技術，蛋白表達純化技術，抗體純化檢測技術轉化到產業化水平，技術涉足分子生物學，生物化學和免疫學等多個領域。目前公司的主要產品包括人類全長cDNA，純化蛋白和抗體，已經推出免疫組化試劑盒，並正在研製一批高技術含量，高附加值的新產品。
英文介紹
The mission of Proteintech Group, Inc is to develop, manufacture a wide spectrum of antibodies against all human proteins known as Human Antibody Projects, thus providing the most effective tools for the identification and quantization of the vast number of known or unknown disease markers. Our philosophy is to be a part of the solution of the research community by providing scientists with every possible antibody they will need and at a reasonable cost. As all founders of the company are bench-side researchers, we have the deepest appreciation for the highest standard of perfection that all scientists hold for their projects, and therefore we hold our products to the same standard. As a part of this research community, we firmly committed to be a silent partner of every research laboratory and every research project.
Therefore it is the responsibility of Proteintech Group to offer researches with a variety of antibodies and related products at highest quality as possible so that the researchers can focus on their creativity, skill and effort as well as funding, without ever having to concern with the quality of reagents used. We also committed to provide them at lowest possible cost because we understand that every dollar of the research grant is the result of hard work of the researchers. Every dollar we saved is a dollar they have earned.
As the silent partner in your research career, you can count on us to solve your supply and technical needs on antibodies and antibody related products. We deeply understand that only if you succeed, we will succeed.
Proteintech Group offers a variety of polyclonal and monoclonal antibodies for your research. Each antibody is thoroughly tested for its ability to perform immunoprecipitation, immunoblotting and immunohistochemistry so that you can be confident in using them. Understanding each antibody has its unique applications and features, we also provide our customers with complete technical support and detailed instructions for each application. To maximize your research flexibility, we promise following services.
The antibody and antibody-related products for research, biotech and clinical diagnostics constitute huge but unsaturated market in the world, and it is subject to a high growth trend. In the US, the National Institute of Health alone receives 17 billion dollars federal funding, among that, 1.7 billion, i.e. 10% is spent on antibody and related reagents. Many private pharmaceutical companies spent many fold more on antibodies and its related products. Another growing market is the proteomic project (project to identify, profile all human proteins and their function), especially in the post genomic project period. Antibodies are the only type of reagents today to solve most problems in the Human Proteomic Project. It is estimated that some 300,000 different anti-human protein antibodies will be needed while there are only 10,000 Antigen specificities are available.
The mission of the Proteintech Group is to design, develop, and market antibody and antibody-chips in the Bioresearch field. The antibody will fill current market that accounts for a minimum of $ 1.7 billion dollars in potential sales. Each product shall be priced to appeal to researchers that stresses lowest cost and convenient.
The procedure of production and marketing has been tested. Projections from studies have shown that with a 2 million dollar initial investment, the company would expect $24 million in sales in year three with a net profit of approximately $20 million. The company would expect to have $38 million in revenue by year five. The company would be self sustained in year one and will be able to break even between year one and two, purely based on antibody production and sales.
In next five years, the estimated market of products yielded from proteomic project would reach to 40 billion. The Proteintech Group is currently developing antibody chips (a collection of thousand antibodies arranged in arrays for quick identification and quantitation of known or unknown proteins in a mixture, such as in blood), a key product of this market. With its advantages of it.
